Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: Data from the Prospective Antifungal Therapy (PATH) registry 2004-2008

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Pfaller, Michael A ^a,b   Andes, David R ^c   Diekema, Daniel J ^b   Horn, David L ^d   Reboli, Annette C ^e   Rotstein, Coleman ^f   Franks, Billy ^g   Azie, Nkechi E ^g  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d David Horn LLC   (United States)

^e Department of Medicine Cooper Medical School of Rowan University ^*  (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHILD; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; DRUG CHOICE; FEMALE; FUNGUS IDENTIFICATION; GRAFT RECIPIENT; HUMAN; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; NORTH AMERICA; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PICHIA GUILLIERMONDII; PRESCRIPTION; PROSPECTIVE STUDY; REGISTER; SOLID TUMOR; SPECIES DISTRIBUTION; SURVIVAL RATE; CANDIDIASIS, INVASIVE; DRUG COMBINATION; DRUG EFFECTS; INFANT; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; PREVALENCE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, INVASIVE; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; INFANT; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; REGISTRIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903777198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101510     Document Type: Article

References (69)

1. Pfaller MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: 1-53.
2. Pfaller MA, Diekema D (2012) The epidemiology of invasive candidiasis. In: Calderone RA, editor. Candida and candidiasis. 2 ed. Washington DC: ASM Press. 449-480.
3. Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, et al. (2009) Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol 47: 3185-3190.
4. Pfaller MA, Diekema DJ (2004) Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42: 4419-4431. (Pubitemid 39362350)
5. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163. (Pubitemid 46167771)
6. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, et al. (2010) Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 48: 1366-1377.
7. Falagas ME, Roussos N, Vardakas KZ (2010) Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 14: e954-966.
8. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, et al. (2012) Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance) registry, 2004-2008. Diagn Microbiol Infect Dis 74: 323-331.
9. Lockhart SR, Messer SA, Gherna M, Bishop JA, Merz WG, et al. (2009) Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol 47: 1216-1217.
10. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ (2009) Identification and susceptibility profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J Clin Microbiol 47: 242-244.
11. Sullivan D, Coleman D (1997) Candida dubliniensis: an emerging opportunistic pathogen. Curr Top Med Mycol 8: 15-25.
12. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, et al. (2013) Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56: 1724-1732.
13. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, et al. (2012) Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 55: 1352-1361.
14. Diekema DJ, Messer SA, Boyken LB, Hollis RJ, Kroeger J, et al. (2009) In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 47: 3170-3177.
15. Pfaller MA, Diekema DJ, Colombo AL, Kibbler C, Ng KP, et al. (2006) Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 44: 3578-3582. (Pubitemid 46768813)
16. Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, et al. (2006) Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 44: 3551-3556. (Pubitemid 46768812)
17. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ng KP, et al. (2008) Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 46: 842-849. (Pubitemid 351379967)
18. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, et al. (2008) Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 46: 515-521. (Pubitemid 351231295)
19. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, et al. (2010) Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata : an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 67: 162-171.
20. Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M (2012) Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia 174: 259-271.
21. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M (2013) Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical isolates (2010-2011): Application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize geographic and temporal trends of antifungal resistance. J Clin Microbiol 51: 2571-2581.
22. Chapeland-Leclerc F, Hennequin C, Papon N, Noel T, Girard A, et al. (2010) Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 54: 1360-1362.
23. Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK, et al. (2011) National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 49: 325-334.
24. Morgan J (2005) Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 7: 429-439.
25. Nguyen MH, Peacock JE, Jr., Morris AJ, Tanner DC, Nguyen ML, et al. (1996) The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100: 617-623. (Pubitemid 26243671)
26. Singh N (2001) Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 7 Suppl 2: 1-7.
27. Snydman DR (2003) Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 123: 500S-503S.
28. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, et al. (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18 Suppl 7: 19-37.
29. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr., Calandra TF, et al. (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503-535.
30. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, et al. (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18 Suppl 7: 53-67.
31. Horn D, Neofytos D (2007) Contemporary patterns in the use of antifungal agents in the treatment of invasive fungal infections: perspectives from registries and databases. Curr Fungal Infect Rep 1: 72-78.
32. Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, Marr KA, et al. (2007) Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 59: 407-414. (Pubitemid 350186332)
33. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, et al. (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34: 7-14. (Pubitemid 33152659)
34. Pammi M, Holland L, Butler G, Gacser A, Bliss JM (2013) Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J 32: e206-216.
35. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T (2006) Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 117: 1680-1687. (Pubitemid 46071397)
36. Forrest GN, Weekes E, Johnson JK (2008) Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 56: 126-129.
37. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, et al. (2011) Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 55: 532-538.
38. Reboli AC (2014) Is the Debate About Treatment of Candida parapsilosis Complex Infections With Echinocandins Much Ado About Nothing? Clin Infect Dis 58: 1422-1423.
39. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, et al. (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54: 1110-1122.
40. Fernandez-Ruiz M, Aguado JM, Almirante B, Lora-Pablos D, Padilla B, et al. (2014) Initial Use of Echinocandins Does Not Negatively Influence Outcome in Candida parapsilosis Bloodstream Infection: A Propensity Score Analysis. Clin Infect Dis 58: 1413-1421.
41. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I (2008) The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112: 2493-2499.
42. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, et al. (2009) Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115: 4745-4752.
43. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ (2004) Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 25: 60-64. (Pubitemid 38139848)
44. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Bijie H, et al. (2009) Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 47: 117-123.
45. Hope W, Morton A, Eisen DP (2002) Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 50: 56-65. (Pubitemid 37554682)
46. Johnson EM (2009) Rare and emerging Candida species. Current Fungal Infection Reports 3: 152-159.
47. Atkinson BJ, Lewis RE, Kontoyiannis DP (2008) Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol 46: 541-546.
48. McClenny NB, Fei H, Baron EJ, Gales AC, Houston AK, et al. (2002) Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob Agents Chemother 46: 1325-1328. (Pubitemid 34415309)
49. Desnos-Ollivier M, Moquet O, Chouaki T, Guerin AM, Dromer F (2011) Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. J Clin Microbiol 49: 2304-2306.
50. Sullivan DJ, Moran GP, Coleman DC (2005) Candida dubliniensis: ten years on. FEMS Microbiol Lett 253: 9-17. (Pubitemid 41605389)
51. Gales AC, Pfaller MA, Houston AK, Joly S, Sullivan DJ, et al. (1999) Identification of Candida dubliniensis based on temperature and utilization of xylose and alpha-methyl-D-glucoside as determined with the API 20C AUX and vitek YBC systems. J Clin Microbiol 37: 3804-3808.
52. Coleman D, Sullivan D, Harrington B, Haynes K, Henman M, et al. (1997) Molecular and phenotypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Dis 3 Suppl 1: S96-101.
53. Pfaller MA, Messer SA, Gee S, Joly S, Pujol C, et al. (1999) In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 37: 870-872. (Pubitemid 29091332)
54. Savini V, Catavitello C, Onofrillo D, Masciarelli G, Astolfi D, et al. (2011) What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast. Mycoses 54: 434-441.
55. Reuter CW, Morgan MA, Bange FC, Gunzer F, Eder M, et al. (2005) Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin Infect Dis 41: 1365-1366. (Pubitemid 41532689)
56. Sendid B, Lacroix C, Bougnoux ME (2006) Is Candida kefyr an emerging pathogen in patients with oncohematological diseases? Clin Infect Dis 43: 666-667. (Pubitemid 44267134)
57. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, et al. (2004) In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn Microbiol Infect Dis 48: 101-105. (Pubitemid 38221504)
58. Fekkar A, Meyer I, Brossas JY, Dannaoui E, Palous M, et al. (2013) Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob Agents Chemother 57: 2380-2382.
59. Beyda ND, Chuang SH, Alam MJ, Shah DN, Ng TM, et al. (2013) Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother 68: 438-443.
60. Desnos-Ollivier M, Ragon M, Robert V, Raoux D, Gantier JC, et al. (2008) Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J Clin Microbiol 46: 3237-3242.
61. Castanheira M, Woosley LN, Diekema DJ, Jones RN, Pfaller MA (2013) Candida guilliermondii and other species of Candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs. J Clin Microbiol 51: 117-124.
62. Colombo AL, Melo AS, Crespo Rosas RF, Salomão R, Briones M, et al. (2003) Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis 46: 253-257.
63. Dubé MP, Heseltine PN, Rinaldi MG, Evans S, Zawacki B (1994) Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin Infect Dis 18: 77-82. (Pubitemid 24025919)
64. Pulimood S, Ganesan L, Alangaden G, Chandrasekar P (2002) Polymicrobial candidemia. Diagn Microbiol Infect Dis 44: 353-357. (Pubitemid 36120713)
65. Klotz SA, Chasin BS, Powell B, Gaur NK, Lipke PN (2007) Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. Diagn Microbiol Infect Dis 59: 401-406. (Pubitemid 350184233)
66. Kim SH, Yoon YK, Kim MJ, Sohn JW (2013) Risk factors for and clinical implications of mixed Candida /bacterial bloodstream infections. Clin Microbiol Infect 19: 62-68.
67. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, et al. (2009) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 37: 1612-1618.
68. Clancy CJ, Nguyen MH (2013) Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56: 1284-1292.
69. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, et al. (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 18 Suppl 7: 9-18.